Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study

• Published in: Cancer research and treatment Vol. 50; no. 2; pp. 488 - 494
• Main Authors: Jung, Ki Sun, Lee, Su Jin, Park, Se Hoon, Lee, Jae-Lyun, Lee, Se-Hoon, Lim, Jae Yun, Kang, Jung Hun, Lee, Suee, Rha, Sun Young, Lee, Kyung Hee, Kim, Ho Young, Lim, Ho Yeong
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Cancer Association 01-04-2018; 대한암학회
• Subjects: Adult; Aged; Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - pathology; Female; Humans; Indazoles; Male; Middle Aged; Original; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; Sulfonamides - pharmacology; Sulfonamides - therapeutic use; 의약학; Phase II study; Non-clear cell renal cell carcinoma; Pazopanib
• ISSN: 1598-2998; 2005-9256
• DOI: 10.4143/crt.2016.584

The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC.
Patientswith locally advanced or metastatic nccRCC, exceptfor collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cyclewas defined as 4weeks and tumorresponsewas evaluated every two cycles. The primary objective was overall response rate (ORR).
A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment-related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay.
In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.